Dentin regeneration in vital pulp therapy: design principles.
The nature and specificity of the mechanisms by which the amputated dentin-pulp interface is therapeutically healed determine the properties of the barrier at this site and play a critical role in the outcome of vital pulp therapy. Healing of the dentin-pulp complex proceeds either by natural repair-which results in defensive hard-tissue formation, or therapeutically regulated dentin regeneration, which aims to reconstitute the normal tissue architecture at the pulp periphery. Progress in biomedical research opens new directions for the design of biologically effective pulp therapies. Application of biocompatible and biodegradable carrier vehicles for local delivery of signaling molecules in pulp-capping situations showed induction of fibrodentin/reparative dentin formation, but often at the expense of underlying pulp tissue. An alternative pre-clinical model aiming to reconstitute normal tissue architecture directly at the dentin-pulp interface should be designed on the basis of the direct induction of odontoblast-like cell differentiation and reparative dentin formation at the pulp-capping material interface. Experimental data clearly showed that pulpal cells can differentiate directly into odontoblast-like cells in association with specific extracellular matrices (dentinal or fibrodentinal matrix) or TGF beta 1-containing artificial substrates. Dentin-induced dentinogenesis can be used as a master plan for the achievement of new therapeutic opportunities. In the present study, several short-term experimental studies on dog teeth for potential direct induction of odontoblast-like cell differentiation at the surface of rhTGF beta 1-containing artificial substrates (Millipore filters, hydroxyapatite granules, calcium hydroxide, pure titanium) failed to induce any specific reparative dentinogenic effects.
Tziafas
D
D
Department of Endodontology, School of Dentistry, Aristotle University of Thessaloniki, 54006 Thessaloniki, Greece. dtziaf@dent.auth.gr
Belibasakis
G
G
Veis
A
A
Papadimitriou
S
S
D000818:Animals; D001672:Biocompatible Materials / Q000737:chemistry / Q000627:therapeutic use; D002126:Calcium Hydroxide / Q000627:therapeutic use; D002454:Cell Differentiation; D003782:Dental Pulp / Q000473:pathology / Q000503:physiopathology*; D003785:Dental Pulp Capping / Q000295:instrumentation / Q000379:methods; D003789:Dental Pulp Exposure / Q000503:physiopathology / Q000628:therapy*; D003804:Dentin / Q000473:pathology / Q000503:physiopathology*; D003809:Dentin, Secondary / Q000503:physiopathology; D003810:Dentinogenesis / Q000502:physiology; D004285:Dogs; D004337:Drug Carriers; D016503:Drug Delivery Systems; D017886:Durapatite / Q000627:therapeutic use; D005109:Extracellular Matrix / Q000502:physiology; D008567:Membranes, Artificial; D008851:Micropore Filters; D009804:Odontoblasts / Q000502:physiology; D012038:Regeneration / Q000502:physiology*; D013499:Surface Properties; D014025:Titanium / Q000627:therapeutic use; D016212:Transforming Growth Factor beta / Q000627:therapeutic use; D053773:Transforming Growth Factor beta1; D014945:Wound Healing / Q000502:physiology
D001672:Biocompatible Materials; D004337:Drug Carriers; D008567:Membranes, Artificial; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; D017886:Durapatite; D014025:Titanium; D002126:Calcium Hydroxide